Analysis Of Income And Expense [Abstract]

Transgene - Filing #2813436

Concept	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Analysis of income and expense [abstract]
Material income and expense [abstract]
Research and development expense	—	—	—	—	—	32 168 EUR	—	—	—	—	—	—	—	—	—	32 883 EUR
Finance income (cost)	—	—	—	—	—	2 900 EUR	—	—	—	—	—	—	—	—	—	3 989 EUR
Selling, general and administrative expense [abstract]
General and administrative expense	—	—	—	—	—	7 912 EUR	—	—	—	—	—	—	—	—	—	7 369 EUR
Revenue and other operating income	—	—	—	—	—	10 344 EUR	—	—	—	—	—	—	—	—	—	17 413 EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	- EUR	- EUR	- EUR	- EUR	- EUR	- EUR	- EUR	- EUR	12,000 EUR	- EUR	- EUR	- EUR	- EUR	- EUR	12,000 EUR	12,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	- EUR	32 804 EUR	- EUR	31 831 EUR	- EUR	31 831 EUR	- EUR	973,000 EUR	372,000 EUR	19 536 EUR	- EUR	- EUR	- EUR	- EUR	19 908 EUR	19 908 EUR
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent	—	—	—	—	—	31 831 EUR	—	—	—	—	—	—	—	—	—	19 908 EUR
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests	—	—	—	—	—	- EUR	—	—	—	—	—	—	—	—	—	- EUR